<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuropsychopharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropsychopharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropsychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-133X</issn>
<issn pub-type="epub">1740-634X</issn>
<publisher>
<publisher-name>Springer International Publishing</publisher-name>
<publisher-loc>Cham</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30061744</article-id>
<article-id pub-id-type="pmc">6300538</article-id>
<article-id pub-id-type="publisher-id">150</article-id>
<article-id pub-id-type="doi">10.1038/s41386-018-0150-5</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6057-2527</contrib-id>
<name>
<surname>Gross</surname>
<given-names>Christina</given-names>
</name>
<address>
<phone>+513 636 3493</phone>
<email>christina.gross@cchmc.org</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Banerjee</surname>
<given-names>Anwesha</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tiwari</surname>
<given-names>Durgesh</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1183-0101</contrib-id>
<name>
<surname>Longo</surname>
<given-names>Francesco</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>White</surname>
<given-names>Angela R.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Allen</surname>
<given-names>A. G.</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schroeder-Carter</surname>
<given-names>Lindsay M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krzeski</surname>
<given-names>Joseph C.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elsayed</surname>
<given-names>Nada A.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Puckett</surname>
<given-names>Rosemary</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klann</surname>
<given-names>Eric</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rivero</surname>
<given-names>Ralph A.</given-names>
</name>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gourley</surname>
<given-names>Shannon L.</given-names>
</name>
<address>
<phone>+404 727 2482</phone>
<email>shannon.l.gourley@emory.edu</email>
</address>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bassell</surname>
<given-names>Gary J.</given-names>
</name>
<address>
<phone>+404 727 3772</phone>
<email>gary.bassell@emory.edu</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9025 8099</institution-id><institution-id institution-id-type="GRID">grid.239573.9</institution-id><institution>Division of Neurology, </institution><institution>Cincinnati Children’s Hospital Medical Center, </institution></institution-wrap>Cincinnati, OH 45229 USA </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2179 9593</institution-id><institution-id institution-id-type="GRID">grid.24827.3b</institution-id><institution>Department of Pediatrics, College of Medicine, </institution><institution>University of Cincinnati, </institution></institution-wrap>Cincinnati, OH 45229 USA </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0941 6502</institution-id><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution>Department of Cell Biology, </institution><institution>Emory University School of Medicine, </institution></institution-wrap>Atlanta, GA 30322 USA </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution>Center for Neural Science, </institution><institution>New York University, </institution></institution-wrap>New York, NY 10003 USA </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0941 6502</institution-id><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution>Department of Pediatrics, </institution><institution>Emory University School of Medicine, </institution></institution-wrap>Atlanta, GA 30322 USA </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0941 6502</institution-id><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution>Department of Psychiatry and Behavioral Sciences, </institution><institution>Emory University School of Medicine, </institution></institution-wrap>Atlanta, GA 30322 USA </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0393 4335</institution-id><institution-id institution-id-type="GRID">grid.418019.5</institution-id><institution>GlaxoSmithKline, </institution></institution-wrap>Collegeville, PA 19426 USA </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0941 6502</institution-id><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution>Yerkes National Primate Research Center, </institution><institution> Emory University School of Medicine, </institution></institution-wrap>Atlanta, GA 30329 USA </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0941 6502</institution-id><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution>Department of Neurology, </institution><institution>Emory University School of Medicine, </institution></institution-wrap>Atlanta, GA 30322 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>13</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2019</year>
</pub-date>
<volume>44</volume>
<issue>2</issue>
<fpage>324</fpage>
<lpage>333</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>1</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>7</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>7</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© American College of Neuropsychopharmacology 2018</copyright-statement>
</permissions>
<abstract id="Abs1">
<p id="Par1">Defects in the phosphoinositide 3-kinase (PI3K) pathway are shared characteristics in several brain disorders, including the inherited intellectual disability and autism spectrum disorder, fragile X syndrome (FXS). PI3K signaling therefore could serve as a therapeutic target for FXS and other brain disorders. However, broad inhibition of such a central signal transduction pathway involved in essential cellular functions may produce deleterious side effects. Pharmacological strategies that selectively correct the overactive components of the PI3K pathway while leaving other parts of the pathway intact may overcome these challenges. Here, we provide the first evidence that disease mechanism-based PI3K isoform-specific inhibition may be a viable treatment option for FXS. FXS is caused by loss of the fragile X mental retardation protein (FMRP), which translationally represses specific messenger RNAs, including the PI3K catalytic isoform p110β. FMRP deficiency increases p110β protein levels and activity in FXS mouse models and in cells from subjects with FXS. Here, we show that a novel, brain-permeable p110β-specific inhibitor, GSK2702926A, ameliorates FXS-associated phenotypes on molecular, cellular, behavioral, and cognitive levels in two different FMRP-deficient mouse models. Rescued phenotypes included increased PI3K downstream signaling, protein synthesis rates, and dendritic spine density, as well as impaired social interaction and higher-order cognition. Several p110β-selective inhibitors, for example, a molecule from the same chemotype as GSK2702926A, are currently being evaluated in clinical trials to treat cancer. Our results suggest that repurposing p110β inhibitors to treat cognitive and behavioral defects may be a promising disease-modifying strategy for FXS and other brain disorders.</p>
</abstract>
<kwd-group kwd-group-type="npg-subject">
<title>Subject terms</title>
<kwd>Diseases of the nervous system</kwd>
<kwd>Cellular neuroscience</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© American College of Neuropsychopharmacology 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>